Clinical characteristics of the 46 TRALI patients from the nested case-control study
| Principal diagnosis . | No. of patients younger than 17 y (n = 15) . | No. of patients older than 16 y (n = 31) . |
|---|---|---|
| Hematologic malignancy* | ||
| ALL, induction chemotherapy | 6 | 0 |
| ALL, consolidation chemotherapy | 1 | 0 |
| AML, induction chemotherapy | 2 | 5 |
| AML, consolidation chemotherapy | 1 (with febrile reaction) | 0 |
| NHL, induction chemotherapy | 1 | 1 |
| NHL, consolidation chemotherapy | 1 | 1 (with GI bleed) |
| Myelodsyplastic syndrome | 0 | 3 (1 with GI bleed) |
| Nonhematological malignancy | ||
| Optic glioma, receiving chemotherapy | 1 | 0 |
| Osteogenic sarcoma, receiving chemotherapy | 1 (with lung abscess) | 0 |
| Prostate cancer with metastasis | 0 | 1 (with DIC) |
| Lung cancer with metastasis | 0 | 1 |
| Cardiac disease* | ||
| Cardiac surgery with cardiopulmonary bypass | 1 | 11 (1 with wound infection) |
| Acute myocardial infarction, bleeding due to platelet dysfunction | 0 | 1 |
| Other | ||
| GI bleed | 0 | 2 (both with cirrhosis) |
| Multiple trauma | 0 | 1 (with HITT) |
| ITP/SLE | 0 | 2 (1 with infected graft) |
| Infection | 0 | 2† |
| Previous transfusion reactions | ||
| None | 9 | 29 |
| Allergic | 4 | 0 |
| Febrile | 2 | 2 |
| Platelet age (oldest product in implicated transfusion), d* | ||
| 2 | 1 | 0 |
| 3 | 1 | 3 |
| 4 | 3 | 9 |
| 5 | 9 | 19 |
| Principal diagnosis . | No. of patients younger than 17 y (n = 15) . | No. of patients older than 16 y (n = 31) . |
|---|---|---|
| Hematologic malignancy* | ||
| ALL, induction chemotherapy | 6 | 0 |
| ALL, consolidation chemotherapy | 1 | 0 |
| AML, induction chemotherapy | 2 | 5 |
| AML, consolidation chemotherapy | 1 (with febrile reaction) | 0 |
| NHL, induction chemotherapy | 1 | 1 |
| NHL, consolidation chemotherapy | 1 | 1 (with GI bleed) |
| Myelodsyplastic syndrome | 0 | 3 (1 with GI bleed) |
| Nonhematological malignancy | ||
| Optic glioma, receiving chemotherapy | 1 | 0 |
| Osteogenic sarcoma, receiving chemotherapy | 1 (with lung abscess) | 0 |
| Prostate cancer with metastasis | 0 | 1 (with DIC) |
| Lung cancer with metastasis | 0 | 1 |
| Cardiac disease* | ||
| Cardiac surgery with cardiopulmonary bypass | 1 | 11 (1 with wound infection) |
| Acute myocardial infarction, bleeding due to platelet dysfunction | 0 | 1 |
| Other | ||
| GI bleed | 0 | 2 (both with cirrhosis) |
| Multiple trauma | 0 | 1 (with HITT) |
| ITP/SLE | 0 | 2 (1 with infected graft) |
| Infection | 0 | 2† |
| Previous transfusion reactions | ||
| None | 9 | 29 |
| Allergic | 4 | 0 |
| Febrile | 2 | 2 |
| Platelet age (oldest product in implicated transfusion), d* | ||
| 2 | 1 | 0 |
| 3 | 1 | 3 |
| 4 | 3 | 9 |
| 5 | 9 | 19 |
Significant concomitant comorbidities are shown in parentheses. All but one patient had absolute neutrophil counts greater than 500/μL. ALL indicates acute lymphoblastic leukemia; AML, acute myeloblastic leukemia; NHL, non-Hodgkin lymphoma; GI, gastrointestinal; ITP/SLE, idiopathic thrombocytopenic purpura/systemic lupus erythematosus; DIC, disseminated intravascular coagulation; and HITT, heparin-induced thrombocytopenia with thrombosis.
Statistically significantly different from the 225 control patients (P < .05). See “Nested case-control study.”
One patient had cholangitis, one had cellulitis.